Geschlechtsspezifische Vorsorge bei erblichem Darmkrebs – Das Lynch-Syndrom

Das Lynch-Syndrom ist eine erbliche Erkrankung, bei der neben kolorektalen Karzinomen auch gynäkologische und andere Tumore gehäuft auftreten. Was in keiner Leitlinie steht: Das Risiko, an diesen Tumoren zu erkranken, hängt sowohl vom Geschlecht als auch vom Genotyp ab. Es ist Zeit für eine geschlechtsspezifische Vorsorge.

• Literatur

• 1 Hampel H, Frankel WL, Martin E et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26: 5783-5788
• 2 Vasen HF, Moslein G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-362
• 3 Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801-818
• 4 Albano WA, Recabaren JA, Lynch HT et al. Natural history of hereditary cancer of the breast and colon. Cancer 1982; 50: 360-363
• 5 Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res 1994; 14: 1635-1639
• 6 Boilesen AE, Bisgaard ML, Bernstein I. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families. Acta Obstet Gynecol Scand 2008; 87: 1129-1135
• 7 Lin KM, Shashidharan M, Thorson AG et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998; 2: 67-71
• 8 Watson P, Vasen HF, Mecklin JP et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123: 444-449
• 9 Capelle LG, Van Grieken NC, Lingsma HF et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010; 138: 487-492
• 10 Goecke T, Schulmann K, Engel C et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 2006; 24: 4285-4292
• 11 Grindedal EM, Moller P, Eeles R et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2460-2467
• 12 van der Post RS, Kiemeney LA, Ligtenberg MJ et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010; 47: 464-470
• 13 Lazar V, Grandjouan S, Bognel C et al. Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. Hum Mol Genet 1994; 3: 2257-2260
• 14 Dolcetti R, Viel A, Doglioni C et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805-1813
• 15 Engel C, Forberg J, Holinski-Feder E et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 2006; 118: 115-122
• 16 Lu KH, Dinh M, Kohlmann W et al. Gynecologic cancer as a „sentinel cancer“ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005; 105: 569-574
• 17 Garg K, Soslow RA. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 2009; 62: 679-684
• 18 Kwon JS, Scott JL, Gilks CB et al. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011; 29: 2247-2252
• 19 Engel C, Rahner N, Schulmann K et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2010; 8: 174-182
• 20 Parry S, Win AK, Parry B et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60: 950-957
• 21 Schmiegel W, Pox C, Reinacher-Schick A et al. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 2010; 48: 65-136
• 22 Teutsch SM, Bradley LA, Palomaki GE et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11: 3-14
• 23 Burt RW, Barthel JS, Dunn KB et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010; 8: 8-61
• 24 Schneider C In Vorbereitung
• 25 Manchanda R, Menon U, Michaelson-Cohen R et al. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Curr Opin Obstet Gynecol 2009; 21: 31-38
• 26 Moslein G, Ohmann C, Wenzel M. [Prophylactic surgery for hereditary non-polyposis colorectal cancer]. Chirurg 2005; 76: 1135-1144
• 27 Schmeler KM, Lynch HT, Chen LM et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354: 261-269
• 28 Weissman SM, Bellcross C, Bittner CC et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome – a review. J Genet Couns 2011; 20: 5-19
• 29 Vasen HF, Mecklin JP, Khan PM et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-425
• 30 Vasen HF, Watson P, Mecklin JP et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-1456
• 31 Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268